Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment
(Thomson Reuters ONE) -
Novartis International AG /
Novartis first company accredited with global "CEO Cancer Gold Standard" for
outstanding efforts in cancer prevention and treatment
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* The non-profit CEO Roundtable on Cancer has recognized the programs Novartis
has to support associates in the prevention, diagnosis and treatment of
cancer
* Originally recognized for these efforts in the US, Novartis has expanded
resources and support to associates worldwide
* Novartis Oncology showcases leadership in the cancer community by continuing
to transform lives of people living with cancer
Basel, August 8, 2013 - Novartis is the first company to earn global CEO Cancer
Gold Standard accreditation by the non-profit organization CEO Roundtable on
Cancer, a group of cancer fighting CEOs from a variety of industries, including
healthcare. The designation recognizes the company's efforts to provide support
to Novartis associates in the prevention, diagnosis and treatment of cancer.
"At Novartis, we believe that everyone should have access to early screening
programs and innovative therapies," said Joseph Jimenez, CEO of Novartis. "Our
efforts for our associates, which are recognized by this designation, are an
extension of our goal to redefine cancer for all patients."
Novartis is passionate about the discovery and development of innovative
medicines to help provide a broad range of new therapies and practical solutions
to advance care of patients. The company's research is driven by a distinctive
scientific and clinical strategy focusing on unmet medical needs and knowledge
of disease pathways. The Novartis research strategy leverages biomarkers and
targeted drug development focused on individual patients. The company's
extensive portfolio of access-to-treatment projects adapts to patients' needs,
products, collaborators and countries.
Novartis first achieved CEO Cancer Gold Standard designation in the US, and
quickly extended these resources around the world. Since then, the company has
offered programs such as:
* adding preventive health services in Portugal
* a yearlong plan on health promotion and its benefits in the Philippines
* regular screenings for colon and breast cancers in Japan and Brazil
The impact has been significant. In fact, through the Novartis cancer screening
program alone, the company has already documented cases of early cancer
detection among our associates and has been able to offer the kind of support
and treatment that helps to change lives. Novartis continues to expand the
program to leverage the company's internal expertise and expand our cancer
network and resources to support employees and their families with the best
medical, emotional and physical support possible.
The CEO Roundtable on Cancer was founded in 2001, when former President George
H.W. Bush challenged a group of executives to "do something bold and venturesome
about cancer within your own corporate families." The CEOs responded by creating
and encouraging the widespread adoption of the CEO Cancer Gold Standard which
calls for organizations to evaluate their health benefits and workplace culture
and take extensive, concrete actions in five key areas of health and wellness to
fight cancer in the workplace.
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "should,"
"efforts," "goal," "continues," or similar expressions. Such forward-looking
statements reflect the current views of the Group regarding future events, and
involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results expressed or
implied by such statements. These expectations could be affected by, among other
things, risks and factors referred to in the Risk Factors section of Novartis
AG's current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update it in the future.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 131,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Beth Calitri
Novartis Global Media Relations Novartis Global Media Relations
+41 61 324 7999 (direct) +41 61 324 7973 (direct)
+41 79 593 4202 (mobile) +41 79 523 0198 (mobile)
eric.althoff(at)novartis.com beth.calitri(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1721823/573533.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1721823]
Unternehmensinformation / Kurzprofil:
Datum: 08.08.2013 - 07:16 Uhr
Sprache: Deutsch
News-ID 285827
Anzahl Zeichen: 7869
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
